BMS Appoints Massacesi to Lead Unified R&D

Company Bristol Myers Squibb Event Type R&D leadership restructuring Modality Multi-modality (oncology, hematology, immunology) Asset Not applicable Target Not applicable Disease Area Oncology; hematology; immunology Summary Bristol Myers Squibb said November 12 that Cristian Massacesi, currently chief medical officer and head of Development, will lead…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *